



PATENT

Docket No.: 19603/4071 (CRF D-2598A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Vivian E. Mack Strong et al.

Serial No. : 09/782,936

Cnfrm. No. : 1665

Filed : February 14, 2001

For : USE OF COX-2 INHIBITORS TO TREAT  
SEPSIS, COMPLICATIONS THEREOF, AND  
EP RECEPTOR MODULATION

Examiner:  
Frederick F. Krass

Art Unit:  
1614

RESPONSE TO COMMUNICATION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


In response to the February 2, 2004, communication from the U.S. Patent and Trademark Office ("PTO"), applicants hereby elect the method of treating patients at risk for systemic inflammatory response syndrome. In addition, applicants confirm the election of sepsis as the sub-modality. These elections are made with traverse. It is submitted that all of the identified groups of invention and species are closely related and, therefore, can be searched and examined together without undue burden on the PTO. Accordingly, it is submitted that the restriction requirement/election of species requirement should be withdrawn.

Respectfully submitted,

Date: March 12, 2004

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600

R754604.1

  
Michael L. Goldman  
Registration No. 30,727

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
Date <u>3/12/04</u>	<u>Wendy L. Barry</u> Wendy L. Barry